Devonian Health Group Inc. (GSD.V)
| Previous Close | 0.2100 |
| Open | 0.2000 |
| Bid | 0.1950 x 0 |
| Ask | 0.2500 x 0 |
| Day's Range | 0.2000 - 0.2000 |
| 52 Week Range | 0.1100 - 0.2750 |
| Volume | |
| Avg. Volume | 5,430 |
| Market Cap | 29.645M |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Jun 30, 2024 - Jul 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireDevonian Health Group Reports Second Quarter 2024 Financial Results and Business Update
QUEBEC CITY, March 28, 2024--Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its second quarter ended on January 31, 2024.
Business WireDevonian Announces Closing of a Private Placement of Units
QUEBEC CITY, March 14, 2024--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $223,800.00 (the "Offering"), effective March 13, 2024. The Offering consisted of the issuance of 1,492,000 units
Business WireDevonian Names Kathryn J. Gregory to the Board of Directors and Grants Stock Options
QUEBEC CITY, February 29, 2024--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the board of directors of the Corporation (the "Board") has appointed pharmaceutical industry veteran Ms. Kathryn J. Gregory to the Board, effective February 28, 2024.
